Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

World Fibrinogen Deficiency (Factor I Deficiency) Therapeutics Report 2016 - Pipeline Review of 5 Companies & 5 Molecules - Research and Markets

Research and Markets
Posted on: 03 Oct 16

Research and Markets has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2016" report to their offering.

Fibrinogen Deficiency (Factor I Deficiency) pipeline therapeutics constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Fibrinogen Deficiency (Factor I Deficiency) Factor I (or fibrinogen) deficiency is a rare inherited bleeding disorder with complications that vary with the severity due to factor I. Factor I deficiency occurs if fibrinogen is missing (Afibrinogenemia) or is present but at a lower level than normal (Hypofibrogenemia), does not function properly (Dysfibrinogenemia) or the clotting reaction is blocked prematurely and the blood clot does not form. Possible treatments include fibrinogen replacement therapy where fibrinogen concentrates are administered to the diseased patient. Plasma and cryoprecipitate are also used for treatment purposes.

The report 'Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III and Phase II stages are 4 and 1 respectively.

Key Topics Covered:

  1. Introduction
  2. Fibrinogen Deficiency (Factor I Deficiency) Overview
  3. Therapeutics Development
  4. Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) - Overview
  5. Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) - Comparative Analysis
  6. Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics under Development by Companies
  7. Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics under Investigation by Universities/Institutes
  8. Fibrinogen Deficiency (Factor I Deficiency) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Fibrinogen Deficiency (Factor I Deficiency) - Products under Development by Companies
  13. Fibrinogen Deficiency (Factor I Deficiency) - Products under Investigation by Universities/Institutes
  14. Fibrinogen Deficiency (Factor I Deficiency) - Companies Involved in Therapeutics Development
  • Biotest AG
  • China Biologic Products, Inc.
  • Grifols, S.A.
  • LFB S.A.
  • Octapharma AG

For more information about this report visit http://www.researchandmarkets.com/research/664frd/fibrinogen

View source version on businesswire.com: http://www.businesswire.com/news/home/20161003006246/en/

Business Wire
www.businesswire.com

Last updated on: 03/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.